Alzheimer's Drug Discovery Foundation Statement on Today's FDA Independent Panel Vote on Biogen's Aducanumab

NEW YORK, Nov. 6, 2020 /PRNewswire/ -- An independent FDA advisory committee today signaled in several votes that it does not believe the clinical study data for Biogen's aducanumab supports the drug's approval for patients with early stage Alzheimer's disease. "Although today's...

from PR Newswire: https://ift.tt/2IbOv8Q